ReviewInternational journal of molecular sciences2011
RNA aptamer evolution: two decades of SELEction.
Review in International journal of molecular sciences, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Honeydew: A Fluorescent Aptamer for Low-Cost Azo Food Dyes.Chembiochem : a European journal of chemical biology · 2026Article
- DNA-Encoded Peptide Library Synthesis and Applications, a Mini-Review.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Aptamer-Based Probes for Cancer Diagnostics and Treatment.Life (Basel, Switzerland) · 2022Review
- Fluorescence-Linked Aptamer Assay for SARS-CoV-2 Spike-Protein: A Step-by-Step Performance Analysis in Clinical Samples.Diagnostics (Basel, Switzerland) · 2022Article
- Generation and Selection of Specific Aptamers TargetingInternational journal of molecular sciences · 2022Article
- HT-SELEX-based identification of binding pre-miRNA hairpin-motif for small molecules.Molecular therapy. Nucleic acids · 2022Article
- Novel Engineered Programmable Systems for ADAR-Mediated RNA Editing.Molecular therapy. Nucleic acids · 2020Review
- Modeling a synthetic aptamer-based riboswitch biosensor sensitive to low hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX) concentrations.PloS one · 2020Article
- Synthetic evolution.Nature biotechnology · 2019Review
- Aptamer-assisted superparamagnetic iron oxide nanoparticles as multifunctional drug delivery platform for chemo-photodynamic combination therapy.Journal of materials science. Materials in medicine · 2019Article
- Intracellular Imaging with Genetically Encoded RNA-based Molecular Sensors.Nanomaterials (Basel, Switzerland) · 2019Review
- Applications of High-Throughput Sequencing for In Vitro Selection and Characterization of Aptamers.Pharmaceuticals (Basel, Switzerland) · 2016Review
- Tunable Riboregulator Switches for Post-transcriptional Control of Gene Expression.ACS synthetic biology · 2015Article
- Particle display: a quantitative screening method for generating high-affinity aptamers.Angewandte Chemie (International ed. in English) · 2014Article
- Screening protein--single stranded RNA complexes by NMR spectroscopy for structure determination.Methods (San Diego, Calif.) · 2014Article
- Stable RNA nanoparticles as potential new generation drugs for cancer therapy.Advanced drug delivery reviews · 2014Review
- Article
- From ugly duckling to swan: unexpected identification from cell-SELEX of an anti-Annexin A2 aptamer targeting tumors.PloS one · 2014Article
- Locked nucleic acid and aptamers.Nucleic acid therapeutics · 2012Article
- Selecting Molecular Recognition. What Can Existing Aptamers Tell Us about Their Inherent Recognition Capabilities and Modes of Interaction?Pharmaceuticals (Basel, Switzerland) · 2012Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aptamers are small non-coding RNAs capable of recognizing, with high specificity and affinity, a wide variety of molecules in a manner that resembles antibodies. This class of nucleic acids is the resulting product of applying a well-established screening method known as SELEX. First developed in 1990, the SELEX process has become a powerful tool to select structured oligonucleotides for the recognition of targets, starting with small molecules, going through protein complexes until whole cells. SELEX has also evolved along with new technologies positioning itself as an alternative in the design of a new class of therapeutic agents in modern molecular medicine. This review is an historical follow-up of SELEX method over the two decades since its first appearance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.